NEWS
Sigmoidoscopy Proves to Be Effective Screening Tool for Colorectal Cancer
In a large randomized trial in healthy men and women aged 55 to 74, sigmoidoscopy substantially reduced the incidence of and mortality from colorectal cancer. Newly diagnosed cases of the disease fell by 21 percent and colorectal cancer deaths fell by 26 percent after a median of 12 years of follow-up.
The findings, from the NCI-funded Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial appeared online May 21 in the New England Journal of Medicine. Read more > >
Panel Reviews Benefits and Harms of CT Scans for Lung Cancer Screening
Cancer organizations issue clinical practice guideline for screeningLung Cancer Drug Shows Promise against Several Childhood Cancers
Crizotinib induced complete responses in some children with ALK gene mutations
Antipsychotic Drug Controls "Breakthrough" Nausea and Vomiting after Chemotherapy
Study is first to demonstrate effective treatment for often-debilitating side effectsTargeted Drug Shows Potential in Advanced Solid Tumors and Brain Metastases
Targeting the BRAF and MEK pathways may increase efficacy while reducing side effectsAlso in the Journals: Laxative-Free CT Colonography Detects Large Polyps
Also in the Journals: Program Helps Older, Overweight Cancer Survivors Lose Weight, Eat Better
Also in the Journals: Coffee Drinking May Be Associated With Lower Risk of Death
A MESSAGE TO READERS
Meet NCI Experts at ASCO 2012
NCI staff will participate in the upcoming American Society of Clinical Oncology's (ASCO) 48th Annual Meeting on June 1–5 at McCormick Place in Chicago, IL.
Attendees can learn about NCI's programs and resources by visiting booth #2047 in the exhibit hall during the meeting. Learn more about NCI-sponsored sessions and activities online, and look for additional highlights from the meeting in the June 12 issue of the NCI Cancer Bulletin.
IN DEPTH
U.S. Preventive Services Task Force Advises against PSA Screening
Benefits of screening do not outweigh harms, task force finds
Featured Clinical Trial: Combining Angiogenesis-Targeted Treatments for Liver Cancer
Will adding experimental antibody to sorafenib improve outcomes for liver cancer patients?
Bridging the Charles River to Find Novel Approaches to Cancer Research
Harvard and MIT Cancer Centers combine their clinical and bioengineering strengths
UPDATES
Notes
- In Memoriam: Cedric Long, Assistant Director of NCI's Division of Extramural Activities
- NCI's Advanced Technology Research Facility Opens
- NCI and China Cancer Institute Discuss Research Issues and Medical Journalism
- Paula Jacobs Appointed Associate Director in NCI's Division of Cancer Treatment and Diagnosis
- Proposals Sought for Use of PLCO Data and Biospecimens
- Cyber-Seminar Will Examine Cancer Control at the State and Local Level
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
